Drug profile · INN
lixisenatide
LYXUMIA
lixisenatide (LYXUMIA) is a glucagon-like peptide 1 receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — lixisenatide
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
lixisenatide (LYXUMIA) is a glucagon-like peptide 1 receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucagon-like peptide 1 receptor agonist
Primary target: Glucagon-like peptide 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lixisenatide?
lixisenatide (LYXUMIA) is a glucagon-like peptide 1 receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for lixisenatide?
LYXUMIA is a marketed brand name for lixisenatide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lixisenatide?
lixisenatide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.